Company: ENTXW
Filing Date: 2025-07-18
Form Type: 8-K
Source: 0001178913-25-002406
Chunk: 1

Company: Entera Bio Ltd.
Filing Date: 2025-07-18
Form: 8-K
Item: Item 5.07
Chunk 1
---
──────────────────
  19,524,779      428,993      542,195          6,197,026  

Proposal 5: Ratification and approval of the Company’s amended and restated compensation policy for the directors and officers of the
Company, as described in the Proxy Statement:

  Votes           Votes                         Broker     
  For             Against      Abstentions      Non-Votes  
 ───────────────────────────────────────────────────────────
  19,520,049      432,623      543,295          6,197,026  

Proposal 6: Ratification and approval, on an advisory, non-binding basis, of the compensation of the Company’s named executive
officers, as described in the Proxy Statement:

  Votes           Votes                         Broker     
  For             Against      Abstentions      Non-Votes  
 ───────────────────────────────────────────────────────────
  19,508,920      443,752      543,295          6,197,026  

Proposal 7: Ratification and approval o f Kesselman &
Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2025, andauthorization of the Company’s Board of Directors, or the Audit Committee, if authorized by the Board of Directors, to determine the compensation of the auditors in accordance with the volume
and nature of their services, as described in the Proxy Statement:

  Votes           Votes                         Broker     
  For             Against      Abstentions      Non-Votes  
 ───────────────────────────────────────────────────────────
  26,617,578      59,966       15,449           0          

No other matters were considered or voted upon at the Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.

                                    ENTERA BIO LTD.                 
  Date: July 18, 2025      By:      /s/ Miranda Toledano            
                                    Name: Miranda Toledano